Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]FB-interleukin-2 is a radiopharmaceutical PET tracer designed to non-invasively image and quantify the infiltration of activated T-lymphocytes in vivo. It consists of the cytokine interleukin-2 (IL-2) conjugated to the positron-emitting radioisotope fluorine-18 via a 4-fluorobenzoyl (FB) prosthetic group. The tracer specifically binds to the high-affinity interleukin-2 receptor (IL-2R), particularly the CD25 (IL-2Rα) subunit, which is highly expressed on activated T-cells and regulatory T-cells (Tregs). By targeting these cells, [18F]FB-interleukin-2 allows for the assessment of the immune response in various conditions, including oncology (to monitor response to immune checkpoint inhibitors), autoimmune diseases, and transplant rejection. It is primarily used in clinical research to identify patients likely to respond to immunotherapy and to monitor treatment efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]FB-interleukin-2.